Search Results - "Likarova, Tereza"

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR) by Špaček, Martin, Smolej, Lukáš, Šimkovič, Martin, Nekvindová, Lucie, Křístková, Zlatuše, Brychtová, Yvona, Panovská, Anna, Mašlejová, Stanislava, Bezděková, Lucie, Écsiová, Dominika, Vodárek, Pavel, Zuchnická, Jana, Mihályová, Jana, Urbanová, Renata, Turcsányi, Peter, Lysák, Daniel, Novák, Jan, Brejcha, Martin, Líkařová, Tereza, Vodička, Prokop, Baranová, Jana, Trněný, Marek, Doubek, Michael

“…Summary Idelalisib (idela), a phosphatidylinositol 3‐kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents…”
Get full text

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL) by Mihalyova, Jana, Panovska, Anna, Simkovic, Martin, Turcsanyi, Peter, Spacek, Martin, Brejcha, Martin, Lysak, Daniel, Mocikova, Heidi, Pavlova, Sarka, Chrapava, Marika, Zuchnicka, Jana, Brychtova, Yvona, Vodarek, Pavel, Urbanova, Renata, Likarova, Tereza, Malcikova, Jitka, Jurkova, Tereza, Lancova, Klara, Bezdekova, Lucie, Papajik, Tomas, Baranova, Jana, Arpas, Tomas, Pospisilova, Sarka, Smolej, Lukas, Doubek, Michael

“…Introduction: Venetoclax in combination with rituximab (VenR) along with either ibrutinib or acalabrutinib monotherapy represent the most common regimens…”
Get full text